Clindamycin hydrochloride

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1970

www.ebi.ac.uk

First approval year: 1970
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Clindamycin hydrochloride
www.ebi.ac.uk

Molecular weight: 461.45
www.ebi.ac.uk

Structure (SMILES): CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1.Cl
www.ebi.ac.uk

cleocin
Cleocin
cleocin hydrochloride
Cleocin hydrochloride
clindamycin hydrochloride
Clindamycin hydrochloride
dalacin c
Dalacin c

antirobe
Antirobe
Clindamycin (as hydrochloride)
clindamycin as hydrochloride
clindamycin hcl
Clindamycin hcl
clindamycin hydrochloride
Clindamycin hydrochloride
CLINDAMYCIN HYDROCHLORIDE [EP MONOGRAPH]
CLINDAMYCIN HYDROCHLORIDE [GREEN BOOK]
CLINDAMYCIN HYDROCHLORIDE [JAN]
CLINDAMYCIN HYDROCHLORIDE [MART.]
CLINDAMYCIN HYDROCHLORIDE [MI]
CLINDAMYCIN HYDROCHLORIDE [ORANGE BOOK]
CLINDAMYCIN HYDROCHLORIDE [USP MONOGRAPH]
CLINDAMYCIN HYDROCHLORIDE [USP-RS]
CLINDAMYCIN HYDROCHLORIDE [VANDF]
Clindamycin hydrochloride [WHO-DD]
clindamycin hydrochloride anhydrous
CLINDAMYCIN HYDROCHLORIDE ANHYDROUS
clindamycin hydrochloride ep monograph
clindamycin hydrochloride green book
clindamycin hydrochloride jan
clindamycin hydrochloride mart
clindamycin hydrochloride mi

And 19 more, listed on the interactive page.

CAS registry numbers

21462-39-5

ChEMBL ID: CHEMBL1200588
www.ebi.ac.uk

InChIKey: AUODDLQVRAJAJM-XJQDNNTCSA-N
www.ebi.ac.uk

FDA ingredient codes (UNII)

T20OQ1YN1W

16051951
118705388

21235
81982

Applicant: PFIZER
Approval date: 22 Feb 1970
Application number: NDA050162

Patents: 0
Designations: 1
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only
Boxed warning: Yes

Drug name stem: -mycin

Administration routes

Oral

Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P02358
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P02359
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P02413
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7J3
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7J7
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7K2
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7K6
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7L0
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7L3
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7L8
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7M2
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7M6
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7M9
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7N1
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7N4
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7N9
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7P5
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7Q1
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7Q6
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7R5
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7R9
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7S3
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7S9
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7T3

And 31 more, listed on the interactive page.

Open Targets mechanisms

Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome

Condition
Infections
Highest recorded phase
4
Condition identifier
EFO:0000544
Subject identifier
D007239
Condition
Osteomyelitis
Highest recorded phase
0.5
Condition identifier
EFO:0003102
Subject identifier
D010019
Condition
Pneumonia
Highest recorded phase
4
Condition identifier
EFO:0003106
Subject identifier
D011014
Condition
Acne Vulgaris
Highest recorded phase
1
Condition identifier
EFO:0003894
Subject identifier
D000152

Condition identifier
EFO_0000544
Condition identifier
EFO_0000544
Highest recorded phase
4
Condition identifier
EFO_0003102
Condition identifier
EFO_0003106
Condition identifier
EFO_0003894
Condition identifier
MONDO_0005249
Highest recorded phase
4
Condition identifier
MONDO_0011438
Highest recorded phase
1

Warning
Black Box Warning
Effect
gastrointestinal toxicity
Warning
Black Box Warning
Effect
infectious disease

Warning
Black Box Warning
Effect
gastrointestinal toxicity
Country
United States
Warning
Black Box Warning
Effect
infectious disease
Country
United States

Event
acute generalised exanthematous pustulosis
Reports
52
Reporting signal score
103.728
Event
clostridium difficile colitis
Reports
30
Reporting signal score
45.6839
Event
drug hypersensitivity
Reports
1,579
Reporting signal score
4,222.71
Event
fall
Reports
5
Reporting signal score
43.9233
Event
fatigue
Reports
26
Reporting signal score
57.0786
Event
pruritus
Reports
137
Reporting signal score
52.3093
Event
pseudomembranous colitis
Reports
25
Reporting signal score
68.3936
Event
rash
Reports
333
Reporting signal score
222.657
Event
rash maculo-papular
Reports
62
Reporting signal score
80.9699
Event
toxic skin eruption
Reports
46
Reporting signal score
78.9748
Event
urticaria
Reports
130
Reporting signal score
80.0301

NCT02099240
clinicaltrials.gov
NCT02593383
clinicaltrials.gov

Dose: 150-300 mg
Route: Oral
How often: Every 6 hours

At least 30 minutes before lying down
Take with a full glass of water (6 to 8 ounces)

Hydrogen bond acceptors: 7
Hydrogen bond donors: 4
Polar surface area: 102.26
Calculated partition coefficient (ALogP): 0.39
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 7
Heavy atoms: 28
Molecular formula: C18H34Cl2N2O5S
Monoisotopic mass: 460.1565488
Natural product: Yes

0009-0225
0009-0331
0009-0395
0904-5959
0904-7194
42571-250
42571-251
42571-252
50268-185
51407-373
51655-317
51655-710
51655-964
55700-761
60760-487
60760-827
60760-828
62135-764
62135-765
62135-766
63187-127
63187-141
63187-247
63304-692
63304-693

And 69 more, listed on the interactive page.

Recorded assays: 151
Active assays: 0

Anti-Bacterial Agents
id.nlm.nih.gov
Protein Synthesis Inhibitors
id.nlm.nih.gov

Related records

Trials (133)

A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS
A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS
A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels.
A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting
A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris
A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris
A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris
Adjunctive Clindamycin for Cellulitis: C4C Trial.
Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

Approved for (1)

Pneumonia

In development for (2)

Acne Phase 1
Osteomyelitis Early phase 1

Clindamycin hydrochloride

Development status

Names and chemistry

Brand names (8)

Other names (44)

Identifiers

PubChem compound IDs (2)

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (56)

Open Targets mechanisms

Investigated indications (4)

Open Targets indications (7)

Warnings (2)

Open Targets warnings (2)

Reported adverse events (11)

Trial references (2)

Dosing

Conditions of use (2)

Chemical properties

National Drug Codes

Evidence counts

Pharmacologic actions

Related records

Trials (133)

Approved for (1)

In development for (2)